文章核心观点 - 华尔街分析师预测Veeva Systems(VEEV)在即将发布的季度财报中,每股收益将达到1.43美元,同比增长57.1%[1] - 预计收入将达到6.4173亿美元,同比增长21.9%[1] 公司财务数据 收入 - 订阅服务收入预计达到5.2826亿美元,同比增长27.4%[6] - 专业服务及其他收入预计达到1.1308亿美元,同比增长1.2%[7] - 其中Veeva R&D Solutions专业服务及其他收入预计达到6833万美元,同比增长2.1%[8] - Veeva R&D Solutions订阅服务收入预计达到2.6779亿美元,同比增长52.8%[9] - Veeva Commercial Solutions订阅服务收入预计达到2.5999亿美元,同比增长8.6%[9] - Veeva Commercial Solutions专业服务及其他收入预计达到4532万美元,同比增长1%[10] 毛利率 - 专业服务及其他业务的非GAAP毛利率预计为26.3%,去年同期为23%[10] - 订阅服务业务的非GAAP毛利率预计为85.2%,去年同期为84.3%[11] 股票表现 - 过去一个月,Veeva股票收益率为2.8%,而标普500指数为4%[12] - 根据Zacks评级,Veeva目前为持有评级,未来表现可能与整体市场相符[12]

With less than half of HCPs now accessible, coordinated engagement across sales, marketing, and medical makes the most of limited time PLEASANTON, Calif., May 23, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today unveiled the latest findings from its Veeva Pulse Field Trends Report. The analysis finds that healthcare professional (HCP) access has returned to its pre-pandemic state. Today, 45% of HCPs are accessible to biopharmas compared to 60% eighteen months ago, with half restricting engagement to th ...

文章核心观点 - Veeva MedTech 连续两年获得"最佳整体医疗技术软件"奖项,表彰其在医疗设备和诊断领域的卓越表现和创新成就 [1][2][3] - Veeva MedTech 凭借深厚的行业专业知识和先进技术,帮助医疗技术公司实现流程的简化和更好的管控 [2] - Veeva MedTech 拥有15年以上的生命科学和医疗技术行业经验,与客户密切合作,推动行业进步 [3] 公司概况 - Veeva Systems 是生命科学行业的全球领导者,提供云端软件解决方案 [6] - Veeva 服务于1000多家客户,从全球最大的生物制药公司到新兴生物技术公司 [6] - Veeva 作为一家公众利益公司,致力于平衡各利益相关方的利益 [6] 产品介绍 - Veeva MedTech 提供端到端的产品生命周期管理,包括Veeva Vault Clinical、Veeva Vault RIM、Veeva Vault Quality、Veeva Vault Commercial和Veeva Medical等应用 [3] - Veeva MedTech 帮助医疗技术公司应对不断变化的监管和市场需求,实现更高效、更快捷和合规的运营 [2][3]

Veeva Systems (VEEV) closed at $209.24 in the latest trading session, marking a -0.34% move from the prior day. This move lagged the S&P 500's daily gain of 0.25%. At the same time, the Dow added 0.17%, and the tech-heavy Nasdaq gained 0.23%. The the stock of provider of cloud-based software services for the life sciences industry has risen by 5.48% in the past month, lagging the Computer and Technology sector's gain of 11.73% and the S&P 500's gain of 7.08%. Market participants will be closely following th ...

Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes BARCELONA, Spain, May 21, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will ...

Veeva Systems (VEEV) recently announced the availability of Vault Basics, a new offering that includes technology, training, and support designed for biotechs. Vault Basics enables rapidly expanding businesses to employ market-leading Veeva Vault applications, without any upfront or maintenance costs. Applications developed on industry best practices can be swiftly adopted by biotechs, providing a basis for scaling and growth management. Vault Basics is live at 10 biotechs to promote speed, compliance, and ...

Delivers industry-leading Vault applications in a turnkey solution with no implementation costs for simple adoption PLEASANTON, Calif., May 16, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of Veeva Vault Basics, a new offering that includes technology, training, and support designed for biotechs. Vault Basics equips fast-growing companies to deploy industry-leading Veeva Vault applications with zero implementation and maintenance costs. Biotechs can quickly adopt applicat ...

Veeva Systems Inc. (VEEV) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter fiscal 2024 performance and strategic deals, is expected to contribute further. Stiff competition and data security threats persist. Over the past six months, this current Zacks Rank #2 (Buy) stock has gained 28.6% compared with 12.6% growth of the industry and a 16.6% rise of the S&P 500 Composite. The renowned provider of cloud-based software app ...

The latest trading session saw Veeva Systems (VEEV) ending at $203.86, denoting a +0.04% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 0.02%. Meanwhile, the Dow lost 0.21%, and the Nasdaq, a tech-heavy index, added 0.29%. Heading into today, shares of the provider of cloud-based software services for the life sciences industry had lost 1.43% over the past month, lagging the Computer and Technology sector's gain of 1.39% and the S&P 500's gain of 1 ...

Veeva Systems (VEEV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this provider of cloud-based software services for the life sciences industry have returned -5.2%, compared to the Zacks S&P 500 composite's -0.2% change. During this period, the Zacks Internet - Software industry, which Veeva falls in, has lost 6.8%. The key question now is: What could ...